Skip to content
NOWCAST Pittsburgh's Action News 4 at 11pm Sunday
Watch on Demand
Advertisement

Pittsburgh researchers using artificial intelligence to help cancer patients

Pittsburgh researchers using artificial intelligence to help cancer patients
INTELLIGENCE. IT STARTS WITH THE CRYOGENICALLY FROZEN TUMOR. PREDICTIVE ONCOLOGY CEO RAYMOND VINER DOESN’T LIKE THE TERM TUMOR TO REFER TO THE CANCER THEY STUDY HERE. I REFER TO THEM AS HUMAN BEINGS. THESE HUMAN BEINGS ARE REPURPOSING THEIR LIVES FOR US, FOR A PURPOSE, TO BE ABLE TO FIND CURES TO HELP THEIR DESCENDANTS. THAT’S THEIR LEGACY. THAT IS NOT A SCIENTIST. HE’S A BUSINESSMAN WHO BUILDS BIOTECH COMPANIES. HE’S HAD A BULL’S EYE ON CANCER FOR 15 YEARS. WHAT’S DIFFERENT ABOUT THIS VENTURE? THE MISSION TO GET CANCER DRUGS THAT WORK TO MARKET YEARS FASTER AND WHAT WOULD HAVE TAKEN 3 TO 5 YEARS AND MILLIONS OF DOLLARS WE WERE ABLE TO DO IN A COUPLE OF CYCLES IN 11, 12, 13 WEEKS IN PRECLINICAL DRUG DEVELOPMENT, TUMOR HETEROGENEITY, PATIENT HETEROGENEITY ISN’T INTRODUCED EARLY ENOUGH. TRANSLATION PREDICTIVE ONCOLOGY SCIENTISTS FOCUSING ON CELL BIOLOGY, MOLECULAR BIOLOGY, COMPUTATIONAL BIOLOGY AND BIOINFORMATICS TO DETERMINE HOW CANCER DRUGS WORK ON REAL HUMAN TUMOR TISSUE, A BANK OF INVALUABLE TUMOR SAMPLES ALLOWS THEM TO CRUNCH THAT DATA FASTER. REMEMBER THOSE SAMPLES ARE PEOPLE. WHEN I THINK ABOUT CANCER, I SEE THEIR FACES. I DON’T. I DON’T SEE CELLS ON A ON A COMPUTER SCREEN. VINER SEES HIS BROTHER ALFRED. HE WAS MY FIRST BEST FRIEND. I GREW UP ALFRED WAS ALWAYS THERE. AND WHENEVER I NEEDED SOMETHING, ALFRED WAS ALWAYS THERE. WHENEVER I WAS FIRST PUNCHED IN THE FACE, IT WAS MY BROTHER WHO PUNCHED ME IN THE FACE. WHENEVER I WHENEVER HE DID THAT, HE WOULD PICK ME UP AND SAY, DON’T EVER DO THAT AGAIN. YOU KNOW, MY BROTHER WAS MY MENTOR. HE ALSO THINKS OF HIS PARENTS. IN MY CASE, MY MOTHER, MY AND MY FATHER AND MY BROTHER. SEQUENTIALLY DIED OF CANCER, WHICH MEANS THAT I WAS A CAREGIVER. MY FAMILY WAS A CAREGIVER, MY SIBLINGS AND MY SISTER WERE CAREGIVERS FOR FIVE CONSECUTIVE YEARS. SENIOR SCIENTIST AMY EWING THINKS OF HER FATHER. MORE RECENTLY, I LOST MY FATHER TO PROSTATE CANCER. ABOUT A YEAR AGO. YEAH, SO TO ME I HAVE A DEEPER UNDERSTANDING NOW OF WHAT IT MEANS TO HAVE ANOTHER DAY OR ANOTHER MONTH OR ANOTHER YEAR. AND I THINK THAT’S REALLY WHAT GETS ME UP IN THE MORNING NOW, EVEN IS TO SAY THAT I WANT TO CARRY ON HIS LEGACY AND HELP SOMEBODY ELSE HAVE MORE TIME WITH THEIR FAMILY MEMBERS, WITH A BOARD OF SCIENTIFIC ADVISORS THAT INCLUDES AN ASTRONAUT AND SOME OF THE TOP SCIENTISTS IN THE COUNTRY. VINER SAYS ETHICS IS PART OF THE ONGOING ARTIFICIAL INTELLIGENCE CONVERSATION. THE PURPOSE IS TO MAKE THE JOB OF THE SCIENTISTS EASIER SO THEY CAN EXPEDITE THE PROCESS OF DISCOVERY. IT’S NOT AI THAT’S GOING TO DO THAT. IT’S THE SCIENTISTS. THEY’RE GOING TO DO THAT IN. AI IS THE TOOL. AI IS THE TOOL THAT SAYS PREDICT IF ONCOLOGY IS AGNOSTIC. THAT MEANS THIS COMPANY SEEKS TO HELP DRUG COMPANIES QUICKLY. ZERO IN ON EFFECTIVE DRUGS FOR ALL KINDS OF CANCER. THE ONES THAT IMPACT LOTS OF PEOPLE LIKE BREAST CANCER AND THE ONES THAT IMPACT RELATIVELY FEW BUT ARE USUALLY A TERMINAL DIAGNOSIS. THINK PANCREATIC CANCER OR GEO BLASTOMA. IF I HAD ANY INFLUENCE OVER THE DRUG DISCOVERY, A DRUG COMPANY DEVELOPING THAT DRUG, I WOULD NAME IT AFTER MY MOTHER. IT WAS GEO BLASTOMA THAT TOOK HIS BROTHER’S LIFE AND HIS MOTHER’S. HIS FATHER, ROSA ISABEL. ROSE. OKAY. ALL RIGHT. STAY TUNED. RIGHT. YEAH. STAY TUNED. STAY TUNED
Advertisement
Pittsburgh researchers using artificial intelligence to help cancer patients
A laboratory in Lawrenceville is harnessing the intellectual talent of Pittsburgh's research institutions to target cancer. We speak with a man on a mission to help cancer patients by using artificial intelligence. It starts with the cryogenically frozen tumor. Predictive Oncology CEO Raymond Vennare doesn't like the term tumor to refer to the cancer they study.“I refer to them as human beings. These human beings are repurposing their lives for us for a purpose, to be able to find cures to help their descendants; that's their legacy,” Vennare said. Vennare is not a scientist. He's a businessman who builds biotech companies. He's had a bullseye on cancer for 15 years.What's different about this venture? The mission: to get cancer drugs that work to market, years faster.“And what would have taken three to five years and millions of dollars, we were able to do in a couple of cycles in 11, 12, 13 weeks,” Vennare said.“In pre-trial drug development tumor heterogeneity, patient heterogeneity isn't introduced early enough,” said Amy Ewing, a senior scientist at Predictive Oncology.Translation: Predictive Oncology's scientists are focusing on cell biology, molecular biology, computational biology and bioinformatics to determine how cancer drugs work on real human tumor tissue.A bank of invaluable tumor samples allows them to crunch that data faster.Remember, those samples are people.“When I think about cancer, I see their faces,” Vennare said. “I don't see cells on a computer screen.”Vennare sees his brother, Alfred.“He was my first best friend. I grew up, Al, Alfred was always there. And whenever I needed something, Alfred was always there.”He also thinks of his parents.“In my case, my mother and my father and my brother sequentially died of cancer, which means I was the caregiver. My family was the caregiver, my siblings and my sister were caregivers for five consecutive years,” he said.Ewing thinks of her father.“I lost my father to prostate cancer about a year ago,” she said. “So to me, I have a deeper understanding now of what it means to have another day, or another month, or another year. I think that's really what gets me up in the morning now is to say that I want to carry on his legacy and help somebody else have more time with their family members.”With a board of scientific advisors that includes an astronaut and some of the top scientists in the country, Vennare says ethics is part of the ongoing artificial intelligence conversation."The purpose is to make the job of the scientist easier, so they can expedite the process of discovery,” he said. “It's not AI that's going to do that, it's the scientists that are going to do that.”Venarre says Predictive Oncology is agnostic, meaning this company seeks to help drug companies quickly zero in on effective drugs for all kinds of cancer.

A laboratory in Lawrenceville is harnessing the intellectual talent of Pittsburgh's research institutions to target cancer. We speak with a man on a mission to help cancer patients by using artificial intelligence.

It starts with the cryogenically frozen tumor. Predictive Oncology CEO Raymond Vennare doesn't like the term tumor to refer to the cancer they study.

Advertisement

“I refer to them as human beings. These human beings are repurposing their lives for us for a purpose, to be able to find cures to help their descendants; that's their legacy,” Vennare said.

Vennare is not a scientist. He's a businessman who builds biotech companies. He's had a bullseye on cancer for 15 years.

What's different about this venture? The mission: to get cancer drugs that work to market, years faster.

“And what would have taken three to five years and millions of dollars, we were able to do in a couple of cycles in 11, 12, 13 weeks,” Vennare said.

“In pre-trial drug development tumor heterogeneity, patient heterogeneity isn't introduced early enough,” said Amy Ewing, a senior scientist at Predictive Oncology.

Translation: Predictive Oncology's scientists are focusing on cell biology, molecular biology, computational biology and bioinformatics to determine how cancer drugs work on real human tumor tissue.

A bank of invaluable tumor samples allows them to crunch that data faster.

Remember, those samples are people.

“When I think about cancer, I see their faces,” Vennare said. “I don't see cells on a computer screen.”

Vennare sees his brother, Alfred.

“He was my first best friend. [When] I grew up, Al, Alfred was always there. And whenever I needed something, Alfred was always there.”

He also thinks of his parents.

“In my case, my mother and my father and my brother sequentially died of cancer, which means I was the caregiver. My family was the caregiver, my siblings and my sister were caregivers for five consecutive years,” he said.

Ewing thinks of her father.

“I lost my father to prostate cancer about a year ago,” she said. “So to me, I have a deeper understanding now of what it means to have another day, or another month, or another year. I think that's really what gets me up in the morning now is to say that I want to carry on his legacy and help somebody else have more time with their family members.”

With a board of scientific advisors that includes an astronaut and some of the top scientists in the country, Vennare says ethics is part of the ongoing artificial intelligence conversation.

"The purpose is to make the job of the scientist easier, so they can expedite the process of discovery,” he said. “It's not AI that's going to do that, it's the scientists that are going to do that.”

Venarre says Predictive Oncology is agnostic, meaning this company seeks to help drug companies quickly zero in on effective drugs for all kinds of cancer.